is glp-1 a peptide vs. Therapy: What's the Difference—and Which Right for You? Oral Small-Molecule GLP-1 Receptor Agonists:

Perou CM, Srlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al

Yuan J, Chen L, Wang J, et al

doi: 10.3390/biomedicines9081029

What to do if you notice bruising, swelling, or irritation

The 2,3-DPG conservation is particularly striking given its importance for functional and therapeutic success in the transfusion of stored RBCs, especially in critically ill patients with compromised vasculature 57

CagriSema, a subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide, is administered once weekly in patients with type 2 diabetes and overweight Novo Nordisk In April 2022, phase 3 clinical trial to evaluate the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one comorbidity apart from diabetes, delivered up to 22.5% weight loss Eli Lilly and Company's In January 2022, the has cleared Altimmune, Inc.s Investigational New Drug (IND) application for the Phase 2 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist under development, indicated for the treatment of obesity and non-alcoholic steatohepatitis (NASH)